Giampaolo Muratore

Dr. Giampaolo Muratore

Department of Surgical Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MIMelania Lo Iacono
Melania Lo Iacono
CMChiara Modica
Chiara Modica
GPGaetana Porcelli
Gaetana Porcelli
OBOrnella Roberta Brancato
Ornella Roberta Brancato
Giampaolo MuratoreGiampaolo Muratore
Giampaolo Muratore
GSGiorgio Stassi
Giorgio Stassi
The tumor microenvironment (TME) plays a key role in promoting and sustaining cancer growth. Adipose tissue (AT), due to its anatomical distribution, is a prevalent component of TME, and contributes to cancer development and progression. Cancer-associated adipocytes (CAAs), reprogrammed by cancer stem cells (CSCs), drive cancer progression by releasing metabolites and inflammatory adipokines. In this review, we highlight the mechanisms underlying the bidirectional crosstalk among CAAs, CSCs, and stromal cells. Moreover, we focus on the recent advances in the therapeutic targeting of adipocyte-released factors as an innovative strategy to counteract cancer progression.

26 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MIMelania Lo Iacono
Melania Lo Iacono
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
PBPaola Bianca
Paola Bianca
OBOrnella Roberta Brancato
Ornella Roberta Brancato
Giampaolo MuratoreGiampaolo Muratore
Giampaolo Muratore
GSGiorgio Stassi
Giorgio Stassi
In a scenario where eco-sustainability and a reduction in chemotherapeutic drug waste are certainly a prerogative to safeguard the biosphere, the use of natural products (NPs) represents an alternative therapeutic approach to counteract cancer diseases. The presence of a heterogeneous cancer stem cell (CSC) population within a tumor bulk is related to disease recurrence and therapy resistance. For this reason, CSC targeting presents a promising strategy for hampering cancer recurrence. Increasing evidence shows that NPs can inhibit crucial signaling pathways involved in the maintenance of CSC stemness and sensitize CSCs to standard chemotherapeutic treatments. Moreover, their limited toxicity and low costs for large-scale production could accelerate the use of NPs in clinical settings. In this review, we will summarize the most relevant studies regarding the effects of NPs derived from major natural sources, e.g., food, botanical, and marine species, on CSCs, elucidating their use in pre-clinical and clinical studies.

28 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
LMLaura Rosa Mangiapane
Laura Rosa Mangiapane
CMChiara Modica
Chiara Modica
VPVincenzo Pantina
Vincenzo Pantina
GPGaetana Porcelli
Gaetana Porcelli
GSGiorgio Stassi
Giorgio Stassi
Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased expression levels of CD44v6 and Myc and retains boosted clonogenic activity along with residual tumorigenic potential. Inhibition of Myc transcription, downstream of the MAPK cascade components, and PI3K pathway activity was able to overcome the protective effects of microenvironmental cytokines, affecting the survival and the clonogenic activity of CR-CSCs, regardless of their mutational background. Likewise, the double targeting induced stabilization of mouse tumor avatars. Altogether, these data outline the rationale for dual kinase targeting of CR-CSCs to prevent their adaptive response, which would lead to disease progression.